Humana Inc vs S&P Global Inc — how do they compare? Humana Inc trades at $400 (market cap $47.81B), while S&P Global Inc trades at $437.02 (market cap $132.71B). The key difference: S&P Global Inc is far larger — about 2.8× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| HUM | SPGI | |
|---|---|---|
Market Cap | $47.81B | $132.71B |
Sector | Health | Financials |
52-Week High | $409.42 | $534.79 |
52-Week Low | $163.67 | $370.42 |
Enterprise Value | $56.85B | $144.68B |
Dividend Yield | 0.89% | 0.87% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
S&P Global (SPGI) trades at $449.75, down 0.24% on the day, with a bullish technical outlook and strong fundamentals. The stock shows robust profitability with a 30.36% net income margin and consistent revenue growth, reaching $15.34B in 2025. Recent corporate actions include the spinoff of Mobility Global, streamlining operations. Analyst consensus is strongly bullish with a $531.11 price target, and technical indicators signal a buy from moving averages despite overbought RSI levels.
The outlook for SPGI is positive, driven by margin expansion targets, AI-driven growth in API usage, and resilient recurring revenues. Key risks include high valuation multiples and sensitivity to debt issuance cycles. Investment opportunity lies in its market-leading position and strategic focus post-spinoff, though investors should monitor execution on growth initiatives and macroeconomic factors affecting capital markets.
Trailing returns across standard periods
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →